Reduction of product composition variability using pooled microbiome ecosystem therapy and consequence in two infectious murine models
Applied and Environmental Microbiology · 2024
DOI: 10.1128/aem.00016-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied and Environmental Microbiology, 2024. Verfasst von Julie Reygner und 14 weiteren Autor:innen. Beteiligte Einrichtung: MaaT Pharma, Lyon, France. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Clostridioides difficile, Clostridium Infections, Disease Models, Animal. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Growing evidence demonstrates the key role of the gut microbiota in human health and disease. The recent success of microbiotherapy products to treat recurrent Clostridioides difficile infection has shed light on its potential in conditions associated with gut dysbiosis, such as acute graft-versus-host disease, intestinal bowel diseases, neurodegenerative diseases, or even cancer. However, the difficulty in defining a “good” donor as well as the intrinsic variability of donor-derived products’ taxonomic composition limits the translatability and reproducibility of these studies. Thus, the pooling of donors’ feces has been proposed to homogenize product composition and achieve higher taxonomic richness and diversity. In this study, we compared the metagenomic profile of pooled products to corresponding single donor-derived products. We demonstrated that pooled products are more homogeneous, diverse, and enriched in beneficial bacteria known to produce anti-inflammatory short chain fatty acids compared to single donor-derived products. We then evaluated pooled products’ efficacy compared to corresponding single donor-derived products in Salmonella and C. difficile infectious mouse models. We were able to demonstrate that pooled products decreased pathogenicity by inducing a structural change in the intestinal microbiota composition. Single donor-derived product efficacy was variable, with some products failing to control disease progression. We further performed in vitro growth inhibition assays of two extremely drug-resistant bacteria, Enterococcus faecium vanA and Klebsiella pneumoniae oxa48, supporting the use of pooled microbiotherapies. Altogether, these results demonstrate that the heterogeneity of donor-derived products is corrected by pooled fecal microbiotherapies in several infectious preclinical models. IMPORTANCE Growing evidence demonstrates the key role of the gut microbiota in human health and disease. Recent Food and Drug Administration approval of fecal microbiotherapy products to treat recurrent Clostridioides difficile infection has shed light on their potential to treat pathological conditions associated with gut dysbiosis. In this study, we combined metagenomic analysis with in vitro and in vivo studies to compare the efficacy of pooled microbiotherapy products to corresponding single donor-derived products. We demonstrate that pooled products are more homogeneous, diverse, and enriched in beneficial bacteria compared to single donor-derived products. We further reveal that pooled products decreased Salmonella and Clostridioides difficile pathogenicity in mice, while single donor-derived product efficacy was variable, with some products failing to control disease progression. Altogether, these findings support the development of pooled microbiotherapies to overcome donor-dependent treatment efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- MaaT Pharma, Lyon, France.
- UMR-S 1139, INSERM, Université Paris Cite, Paris, France.
- UMR1319, Micalis Institute, INRAE, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France.
- Team GIMAP, Centre International de Recherche en Infectiologie, Université Jean Monnet, Saint-Etienne, France.
- Inserm, Université Claude Bernard Lyon, Lyon, France.
- CIC 1408 Inserm Vaccinology, University Hospital of Saint-Etienne, Saint-Etienne, France.
ORCID-Profile: Stéphane Paul, Anne-Judith Waligora-Dupriet, Bastien Laperrousaz
Zitieren
APA
Reygner, J., Delannoy, J., Barba-Goudiaby, M. T., Gasc, C., Levast, B., Gaschet, E., Ferraris, L., Paul, S., Kapel, N., Waligora-Dupriet, A. J., Barbut, F., Thomas, M., Schwintner, C., Laperrousaz, B., & Corvaïa, N. (2024). Reduction of product composition variability using pooled microbiome ecosystem therapy and consequence in two infectious murine models. Applied and Environmental Microbiology. https://doi.org/10.1128/aem.00016-24
Vancouver
Reygner J, Delannoy J, Barba-Goudiaby MT, Gasc C, Levast B, Gaschet E, et al. Reduction of product composition variability using pooled microbiome ecosystem therapy and consequence in two infectious murine models. Applied and Environmental Microbiology. 2024. doi:10.1128/aem.00016-24
BibTeX
@article{Reygner2024,
author = {Reygner, Julie and Delannoy, Johanne and Barba-Goudiaby, Marie-Thérèse and Gasc, Cyrielle and Levast, Benoît and Gaschet, Enora and Ferraris, Laurent and Paul, Stéphane and Kapel, Nathalie and Waligora-Dupriet, Anne-Judith and Barbut, Frederic and Thomas, Muriel and Schwintner, Carole and Laperrousaz, Bastien and Corvaïa, Nathalie},
title = {Reduction of product composition variability using pooled microbiome ecosystem therapy and consequence in two infectious murine models},
journal = {Applied and Environmental Microbiology},
year = {2024},
doi = {10.1128/aem.00016-24}
}
EUVIMED